Biosimilar Monoclonal Antibodies Market Report 2026

The biosimilar monoclonal antibodies market size has grown strongly in recent years. It will grow from $10.64 billion in 2025 to $11.29 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to high cost of originator biologics, growing burden of chronic and autoimmune diseases, patent expirations of blockbuster monoclonal antibodies, increasing healthcare expenditure, gradual regulatory clarity for biosimilars.

The biosimilar monoclonal antibodies market size is expected to see strong growth in the next few years. It will grow to $14.58 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to expansion of biosimilar pipelines, rising demand for affordable biologic treatments, increasing approvals in emerging markets, advancements in biopharmaceutical manufacturing, supportive government policies for biosimilar adoption. Major trends in the forecast period include rising adoption of cost-effective biosimilar monoclonal antibodies, increasing use of biosimilars in oncology and autoimmune disorders, growing physician and patient acceptance of biosimilars, expansion of regulatory approvals across global markets, increased focus on improving access to biologic therapies.

The increasing incidence of autoimmune diseases is expected to drive the growth of the biosimilar monoclonal antibodies market in the coming years. Autoimmune diseases are a group of conditions in which the immune system mistakenly attacks the body’s own tissues and organs. The rise in autoimmune disorders is largely attributed to growing exposure to environmental triggers such as pollution and chemicals, which can disrupt immune system regulation and lead to abnormal immune responses. Biosimilar monoclonal antibodies help address the growing burden of autoimmune diseases by offering affordable, effective, and widely accessible targeted therapies that help control excessive immune activity in affected patients. For example, in February 2024, according to Arthritis Australia, an Australia-based non-profit organization, it was projected that in 2025 approximately 212,136 males and 362,137 females would be living with rheumatoid arthritis, with these numbers expected to increase by 2040 to about 280,040 males and 479,828 females. Consequently, the rising incidence of autoimmune diseases is contributing to the growth of the biosimilar monoclonal antibodies market.

Major companies operating in the biosimilar monoclonal antibody market are focusing on developing biosimilar versions of monoclonal antibody therapies to provide cost-effective alternatives to originator biologics, thereby improving affordability and access within healthcare systems. An intravenous formulation refers to an antibody preparation designed for direct administration into the bloodstream through a vein to achieve rapid therapeutic effects. For instance, in May 2024, Bio-Thera Solutions, a China-based biopharmaceutical company, together with Biogen Inc., a US-based biopharmaceutical company, launched TOFIDENCE (tocilizumab-bavi) in an intravenous formulation in the United States. TOFIDENCE received approval from the US Food and Drug Administration in September 2023 for the treatment of moderately to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis. At launch, the product was made available in three vial sizes - 80 mg/4 mL, 200 mg/10 mL, and 400 mg/20 mL - for intravenous infusion, with subcutaneous versions planned for future introduction.

In October 2025, Ipca Laboratories Limited, an India-based pharmaceutical company, entered into a partnership with BioSimilar Sciences PR LLC to develop and manufacture next-generation biosimilars for the US market, including anti-cancer and anti-inflammatory monoclonal antibodies. Through this collaboration, Ipca and BioSimilar Sciences aim to combine their scientific and manufacturing capabilities by leveraging Ipca’s expertise in biosimilar development and BioSimilar Sciences’ 200,000-square-foot sterile manufacturing facility in Aguadilla, Puerto Rico. The partnership is intended to accelerate clinical manufacturing, optimize production timelines, and improve global access to affordable biologic medicines. BioSimilar Sciences PR LLC is a US-based biotechnology company specializing in advanced biologics manufacturing and regulatory-compliant sterile filling services.

Major companies operating in the biosimilar monoclonal antibodies market are Pfizer Inc., Novartis AG, AbbVie Inc., Coherus BioSciences, Biocon Limited, Amgen Inc., Boehringer Ingelheim International GmbH, Celltrion Inc., BioXpress Therapeutics SA, Intas Pharmaceuticals Limited, Genor BioPharma Co. Ltd., BIOCAD, Dr. Reddy's Laboratories Ltd., 3SBio Inc., Reliance Life Sciences, Hisun Pharmaceuticals, Celgen Biopharmaceuticals, Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd., Shanghai Henlius Biotech Inc., Teva Pharmaceutical Industries Ltd., Alvotech, Xentria Inc., Lazuline Biotech Private Limited, Epygen Biotech Pvt Ltd., Mabpharm Limited, Qilu Pharmaceutical Co. Ltd., Chiatai Tianqing Pharmaceutical Group Co. Ltd., YL Biologics Ltd., Aprogen Biologics, UNDBIO Co Ltd., Samsung Bioepis Co. Ltd., ISU Abxis Corp., Bio-Rad Laboratories Inc.

North America was the largest region in the biosimilar monoclonal antibodies market in 2025. The regions covered in the biosimilar monoclonal antibodies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biosimilar monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the biosimilar monoclonal antibodies market by increasing costs associated with imported biologics, raw materials, and biomanufacturing equipment, thereby affecting overall production economics. Segments such as infliximab, rituximab, and trastuzumab biosimilars are particularly affected, with regions like North America and parts of Europe experiencing pricing and supply challenges due to reliance on global supply chains. However, tariffs have also encouraged local manufacturing, regional partnerships, and investments in domestic biopharmaceutical capabilities, supporting long-term market sustainability and competitive pricing.

The biosimilar monoclonal antibodies market research report is one of a series of new reports that provides biosimilar monoclonal antibodies market statistics, including biosimilar monoclonal antibodies industry global market size, regional shares, competitors with a biosimilar monoclonal antibodies market share, detailed biosimilar monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the biosimilar monoclonal antibodies industry. This biosimilar monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biosimilar monoclonal antibodies are a category within the biosimilars family and consist of large, complex protein molecules. They are commonly used in the treatment of conditions such as cancer and rheumatoid arthritis. These antibodies play a role in the immune system by identifying and helping eliminate foreign substances, including bacteria, viruses, and other pathogens.

The primary types of biosimilar monoclonal antibodies include synthetic chemicals, biopharmaceuticals, and others. A biopharmaceutical, also referred to as a biologic or biologic medical product, is any pharmaceutical drug that is produced from, derived from, or partially synthesized using biological sources. The main compounds include infliximab, rituximab, abciximab, trastuzumab, adalimumab, and bevacizumab, which are used across various applications such as chronic and autoimmune diseases, oncology, and others.

The biosimilar monoclonal antibodies market consists of sales of Blitzima, Ritemvia, Rituzena, and Truxima. Values in this market are """"factory gate values,"""" that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.